ArticleJournal of translational medicine2015

Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis.

Catriona Jamieson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.